188 related articles for article (PubMed ID: 9815845)
21. Persistent decrease in proliferative potential of marrow CD34(+)cells exposed to early-acting growth factors after autologous bone marrow transplantation.
Domenech J; Cartron G; Clement N; Estienne MH; Herault O; Truglio D; Benboubker L; Roingeard F; Desbois I; Colombat P; Binet C
Bone Marrow Transplant; 2002 Apr; 29(7):557-62. PubMed ID: 11979303
[TBL] [Abstract][Full Text] [Related]
22. Comparison of peripheral blood stem cells mobilized with granulocyte colony-stimulating factor with or without prior standard-dose chemotherapy in patients with malignancy.
Kobayashi N; Kasai M; Masauzi N; Ogasawara M; Kiyama Y; Naohara T; Higa T; Hashino S; Tanaka J; Imamura M
Jpn J Clin Oncol; 1995 Dec; 25(6):250-7. PubMed ID: 8523821
[TBL] [Abstract][Full Text] [Related]
23. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
[TBL] [Abstract][Full Text] [Related]
24. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients--results of a phase I/II trial.
Moskowitz CH; Stiff P; Gordon MS; McNiece I; Ho AD; Costa JJ; Broun ER; Bayer RA; Wyres M; Hill J; Jelaca-Maxwell K; Nichols CR; Brown SL; Nimer SD; Gabrilove J
Blood; 1997 May; 89(9):3136-47. PubMed ID: 9129016
[TBL] [Abstract][Full Text] [Related]
25. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
26. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
27. Analysis of peripheral blood CD34+ cells mobilized with granulocyte colony-stimulating factor (G-CSF) using a long-term culture system.
Suzuki T; Muroi K; Amemiya Y; Miura Y
Bone Marrow Transplant; 1998 Apr; 21(8):751-7. PubMed ID: 9603397
[TBL] [Abstract][Full Text] [Related]
28. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation.
Körbling M; Anderlini P; Durett A; Maadani F; Bojko P; Seong D; Giralt S; Khouri I; Andersson B; Mehra R; vanBesien K; Mirza N; Przepiorka D; Champlin R
Bone Marrow Transplant; 1996 Dec; 18(6):1073-9. PubMed ID: 8971375
[TBL] [Abstract][Full Text] [Related]
29. Recombinant human interleukin-3 (rhIL-3) enhances the mobilization of peripheral blood progenitor cells by recombinant human granulocyte colony-stimulating factor (rhG-CSF) in normal volunteers.
Huhn RD; Yurkow EJ; Tushinski R; Clarke L; Sturgill MG; Hoffman R; Sheay W; Cody R; Philipp C; Resta D; George M
Exp Hematol; 1996 Jun; 24(7):839-47. PubMed ID: 8647235
[TBL] [Abstract][Full Text] [Related]
30. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
[TBL] [Abstract][Full Text] [Related]
31. Dendritic cell-based vaccines in the setting of peripheral blood stem cell transplantation: CD34+ cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells.
Choi D; Perrin M; Hoffmann S; Chang AE; Ratanatharathorn V; Uberti J; McDonagh KT; Mulé JJ
Clin Cancer Res; 1998 Nov; 4(11):2709-16. PubMed ID: 9829733
[TBL] [Abstract][Full Text] [Related]
32. Highly efficient gene transfer into preterm CD34 hematopoietic progenitor cells.
Shields LE; Kiem HP; Andrews RG
Am J Obstet Gynecol; 2000 Sep; 183(3):732-7. PubMed ID: 10992201
[TBL] [Abstract][Full Text] [Related]
33. Effects of glycosylated and non-glycosylated G-CSFs, alone and in combination with other cytokines, on the growth of human progenitor cells.
Pedrazzoli P; Gibelli N; Pavesi L; Preti P; Piolini M; Bertolini F; Robustelli della Cuna G
Anticancer Res; 1996; 16(4A):1781-5. PubMed ID: 8712701
[TBL] [Abstract][Full Text] [Related]
34. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
35. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
[TBL] [Abstract][Full Text] [Related]
36. Cytokine mobilization of peripheral blood stem cells in patients with Gaucher disease with a view to gene therapy.
Nimgaonkar M; Mierski J; Beeler M; Kemp A; Lancia J; Mannion-Henderson J; Mohney T; Bahnson A; Rice E; Ball ED
Exp Hematol; 1995 Dec; 23(14):1633-41. PubMed ID: 8542958
[TBL] [Abstract][Full Text] [Related]
37. Characterization of CD34+ subsets derived from bone marrow, umbilical cord blood and mobilized peripheral blood after stem cell factor and interleukin 3 stimulation.
De Bruyn C; Delforge A; Lagneaux L; Bron D
Bone Marrow Transplant; 2000 Feb; 25(4):377-83. PubMed ID: 10723580
[TBL] [Abstract][Full Text] [Related]
38. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
[TBL] [Abstract][Full Text] [Related]
40. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
